The claimed [no resistance] is clearly stated on their slide for their NUCLEAR study presented this morning at the Cowen conf.. As AF pointed out, it is ludicrous to even mention the word for a trial that ended at Day 14. It is more absurd for analysts to take the Phase 1 data so seriously.
We only have to remember that most nucleoside analogs failed so far. Roche's R1626, Idenix drugs, etc. A research paper describing the trial data for R1626 stated identical claims as the VRUS management is doing right now. Ask what happened to R1626.